BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Rhea-AI Summary

BriaCell Therapeutics (NASDAQ: BCTX) has been selected to join Memorial Sloan Kettering Cancer Center's (MSK) Therapeutics Accelerator 2025 Cohort program to advance the development of its Bria-OTS+™ immunotherapy platform. The collaboration aims to accelerate the clinical development of BriaCell's next-generation personalized off-the-shelf immunotherapy for multiple cancer indications, including metastatic breast cancer and prostate cancer.

Through this program, BriaCell will gain access to MSK's extensive expertise and institutional resources, including GMP manufacturing services, IND Application support, and regulatory strategy assistance. MSK, with over 135 years of leadership in cancer care, will provide crucial support to expedite Bria-OTS+ development.

Positive

• Selection for prestigious MSK Therapeutics Accelerator program validates technology potential
• Access to MSK's GMP manufacturing and regulatory expertise can accelerate development
• Potential expansion into multiple cancer indications beyond breast cancer

Negative

• Early-stage development with no immediate revenue potential
• Clinical development timeline and success remain uncertain

Insights

Biotechnology Research Analyst

BriaCell's selection for MSK's accelerator program provides valuable development resources for Bria-OTS+, potentially accelerating their cancer immunotherapy to clinical trials.

BriaCell's acceptance into Memorial Sloan Kettering's Therapeutics Accelerator program represents a significant operational milestone for their next-generation personalized immunotherapy platform. The collaboration gives BriaCell access to MSK's GMP manufacturing capabilities, regulatory expertise, and assistance with IND preparation – critical components that typically represent substantial bottlenecks in development timelines.

The selection by MSK, one of the world's premier cancer research institutions, provides external validation for BriaCell's Bria-OTS+ technology. This personalized off-the-shelf approach aims to address multiple cancer types including metastatic breast cancer and prostate cancer, potentially expanding BriaCell's addressable market.

While this announcement doesn't provide specific clinical data or timeline acceleration metrics, it establishes important infrastructure support that could help BriaCell navigate the complex regulatory pathway more efficiently. The IND preparation assistance is particularly valuable as it directly impacts the timeline to human clinical trials. For an emerging biotech company, these institutional resources can significantly reduce development costs while potentially improving the quality of regulatory submissions.

Investors should view this as a positive operational development that strengthens BriaCell's development capabilities, though the ultimate value depends on successful execution and eventual clinical outcomes with Bria-OTS+.

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce its acceptance into Memorial Sloan Kettering Cancer Center’s (MSK’s) Therapeutics Accelerator 2025 Cohort program. This project aims to accelerate the clinical development of Bria-OTS+, BriaCell’s next generation personalized off-the-shelf immunotherapy, for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers.

As one of the world’s foremost cancer research and treatment institutions, MSK has more than 135 years of leadership in patient care, education and discovery. Through the MSK Therapeutics Accelerator Cohort program, BriaCell will explore access to MSK’s expertise and institutional resources, including GMP manufacturing services, Investigational New Drug (IND) Application preparation and submission and regulatory strategy support to expedite Bria-OTS+ development.

“We are honored to work with the scientific and clinical experts at MSK Therapeutics Accelerator,” stated Dr. William V. Williams, BriaCell’s President and CEO. “MSK’s deep expertise in cancer therapy development and state-of-the-art resources make it an ideal partner to accelerate our personalized off-the-shelf immunotherapy platform.”

“We are excited to welcome BriaCell into the cohort program,” stated Eileen Flowers, PhD, Director, Technology Development & Licensing, in the Office of Entrepreneurship and Commercialization at MSK.

“We believe Bria-OTS+ has the potential to transform cancer care, offering meaningful advances in efficacy and safety for thousands of patients,” stated Dr. Miguel Lopez-Lago, BriaCell’s Chief Scientific Officer. “Our participation in this cohort program is yet another step towards achieving that vision.”

About BriaCell Therapeutics Corp.

BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.

Safe Harbor

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release, including statements regarding the Company’s beliefs that the collaboration with the Memorial Sloan Kettering Cancer Center could propel the clinical development of Bria-OTS+; the specific topics that the MSK Therapeutics Accelerator Cohort will explore and discuss; the Company exploring access to MSK’s expertise and institutional resources; and the Company’s beliefs regarding Bria-OTS+’s potential to transform cancer care and offer meaningful advances in efficacy and safety for thousands of patients, are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com 

Investor Relations Contact:
investors@briacell.com

FAQ

What is the significance of BriaCell's (BCTX) selection for MSK's 2025 Therapeutics Accelerator Program?

The selection provides BriaCell access to MSK's expertise, GMP manufacturing services, and regulatory support to accelerate the development of Bria-OTS+™ immunotherapy for multiple cancer indications.

What cancer types will BriaCell's (BCTX) Bria-OTS+™ immunotherapy target?

Bria-OTS+™ will target multiple cancer indications, including metastatic breast cancer, prostate cancer, and other cancers.

What resources will Memorial Sloan Kettering provide to BriaCell (BCTX)?

MSK will provide GMP manufacturing services, IND Application preparation and submission support, regulatory strategy assistance, and access to their institutional expertise.

How will the MSK Accelerator Program benefit BriaCell's (BCTX) development timeline?

The program is expected to expedite Bria-OTS+ development through access to MSK's expertise, manufacturing capabilities, and regulatory support services.

What is Bria-OTS+™ and how does it work?

Bria-OTS+™ is a next-generation personalized off-the-shelf immunotherapy designed to transform cancer care by potentially offering advances in efficacy and safety for cancer patients.